CFD and atrophic macular degeneration: Recently, ROCHE announced that the clinical trial (phase IIB) for Lampalizumab (NCT01602120), an antibody-binding fragment of a humanized monoclonal antibody that binds to complement factor D, which has been implicated in the pathogenesis of geographic atrophy61, did not reduced the geographic atrophy lesion area at 1 year of treatment62.